 Harmony Biosciences crushed expectations Tuesday, citing a growing number of narcolepsy patients on its drug, and the biotech stock surged. The post Harmony Biosciences Makes Leap Out Of Buy Zone After Narcolepsy Drug Drives Beat appeared first on Investors Business Daily. 